Navigation Links
GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
Date:3/15/2012

GAITHERSBURG, Md., March 15, 2012 /PRNewswire/ -- Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the fourth quarter and year ended December 31, 2011.  For the year ended December 31, 2011, the Company reported a net loss of $7.4 million, or $0.58 per share, compared with a net loss of $12.3 million, or $0.97 per share, for the year ended December 31, 2010. GenVec ended the year with $26.4 million in cash, cash equivalents, and short-term investments.  

"In 2011 we made significant progress in our hearing loss program, partnered with Novartis, and advanced the development of our attractive portfolio of vaccine opportunities. We also enhanced our differentiated, proprietary core technology, adding further value to our product pipeline. We believe 2012 has the potential for important advances in these programs," stated Paul H. Fischer, Ph.D., GenVec's President and CEO.

2011 and Recent Corporate Highlights

  • We extended our Research Collaboration and License Agreement with Novartis (NYSE: NVS).  Under the extension, Novartis will fund research at GenVec through January 2013 to support its hearing loss and balance disorders program.
  • We achieved the second milestone in our research collaboration with Novartis which was triggered by the successful completion of certain preclinical development activities.  After this achievement, we are eligible to receive up to an additional $206.0 million in milestone payments if certain clinical, regulatory, and sales milestones are met, in addition to royalties on future sales.
  • Research was published describing how GenVec technology, utilizing a vector targeted to supporting cells and limited in expression to those cells, can be used to restore balance function in an animal model.
  • We expanded our relationship with Merial, initially focused on the development of
    '/>"/>

  • SOURCE GenVec, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. GenVec President and Chief Executive Officer Announces Retirement
    2. GenVec Achieves Second Milestone in Collaboration
    3. GenVec to Present at the 2011 10th Annual BIO Investor Forum
    4. GenVec Renews Stockholder Rights Plan
    5. GenVec Reports First Quarter 2011 Financial Results
    6. GenVec Regains Compliance with NASDAQ Listing Requirements
    7. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
    8. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
    9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
    10. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
    11. GenVec Reports Third Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
    (Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
    (Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
    (Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
    Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
    ... - Wisconsin manufacturers made $215 million in efficiency ... Wisconsin Manufacturers Extension Partnership (WMEP) during the organization's last ... is a state-supported, non-profit organization providing consulting services to ... was based on a survey of its clients. It ...
    ... - The Wisconsin Economic Summit served its purpose ... four summits that took place between 2000 and 2003 ... that are shaping the state's growth. But once those ... to do something about them, the Wisconsin Economic Summit ...
    ... conference on protecting the U.S. food supply from terrorism and ... until spring from its original November dates. , ,The ... 1-3 in downtown Milwaukee, with as many as 1,000 people ... David Duecker, who, with the Wisconsin Procurement Institute, is helping ...
    Cached Biology Technology:Manufacturing group says efforts led to big improvements 2Forum builds on the work of the Wisconsin Economic Summit 2Forum builds on the work of the Wisconsin Economic Summit 3
    (Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
    (Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E - ... authentication solutions, today announced it will showcase its EyeLock ID ... by the Department of Energy,s Oak Ridge National Laboratory ... Show . EyeLock,s iris identity authentication technology is being used ...
    (Date:1/22/2015)... OXFORD, Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... growing mobile commerce market, reports on the recent success of the Wocket™ ... Wocket smart wallet was named as one of the ... of the "5 Best Products Launched At CES So Far" by Newseveryday.com ...
    Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
    ... have developed a way to produce sharp fluid jets with ... living cell. The technique promises a way to deliver drugs ... be very valuable for research involving stem cells and other ... the APS journal Physical Review Letters . The ...
    ... - Greenhouse gas markets, where invisible gases are ... people. Farmers can make money on these markets, ... methane capture technologies in animal-based systems, no-till farming, ... extension educators, offset aggregators, and other stakeholders need ...
    ... release is available in German . , Spectroscopic ... can look inside materials. They exploit the interaction of light ... absorption spectroscopy, researchers from Helmholtz-Zentrum Berlin fr Materialien und Energie ... to solvent so-called electron transfer. They can even make ...
    Cached Biology News:Greenhouse gas calculator connects farming practices with carbon credits 2Help from the dark side 2
    ... suitable for use with RNA. ... with 0.1% diethylpyrocarbonate (DEPC) and ... DEPC.DNase/RNase-Free Distilled WaterDistilled Water is ... molecular biology applications. It is ...
    IHC detection kit for BrdU in cells and tissues...
    Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
    The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
    Biology Products: